Integrity CE
Oncology & Hematology
Integrity CE
The Evolving Treatment Journey for Patients With Unresectable Stage III NSCLC in the Era of Immune Therapy
FEATURING
Ticiana Leal
- 80 views
- January 26, 2024
Integrity CE
Case Discussion: 59 y/o Former Smoker With Stage 3A NSCLC
FEATURING
Ticiana Leal
- 100 views
- January 26, 2024
- 1
Integrity CE
SABCS 2023 Summary: "monarchE & NATALEE Trials - Adjuvant Treatment in Patients With HR+/HER2- eBC"
FEATURING
Aditya Bardia
- 388 views
- January 26, 2024
- 3
Integrity CE
SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & Fulvestrant for Aromatase Inhibitor-Resistant HR+/HER2- Advanced BC"
FEATURING
Aditya Bardia
- 1,245 views
- January 26, 2024
- 8
Integrity Continuing Education
SABCS 2023 Insights: "TROPION-Breast01 - Dato-DXd Compared to Chemo in Advanced HR+/HER2- BC"
FEATURING
Aditya Bardia
- 162 views
- January 26, 2024
- 1
Integrity CE
Cervical Chronicles: Navigating the Evolving Landscape of Treatment
FEATURING
Martina Murphy
- 72 views
- January 24, 2024
- 1
Integrity CE
ASH 2023 Insights: "PERSEUS Study - Daratumumab With VRd vs. VRd in NDMM Eligible for ASCT”
FEATURING
Ola Landgren
- 236 views
- January 24, 2024
Integrity Continuing Education
Collaborative Care in MF - Community and Academic Physicians Discuss Managing a Complicated Case
FEATURING
Luke Fletcher,
Aaron Gerds
- 21 views
- January 24, 2024
Integrity Continuing Education
SABCS 2023 Summary: "Clinical Updates in HER2+ BC"
FEATURING
Paolo Tarantino
- 95 views
- January 24, 2024
Integrity CE
Health Disparities in Endometrial Cancer
FEATURING
Martina Murphy
- 17 views
- September 7, 2023
Integrity Continuing Education
A Brief Review of Ongoing NSCLC Clinical Trials
FEATURING
Justin Gainor,
Jacob Sands
- 85 views
- September 5, 2023
- 1
Integrity Continuing Education
40 y/o Male With Stage 3A NSCLC: Treatment Options
FEATURING
Justin Gainor,
Jacob Sands
- 55 views
- September 5, 2023
Integrity Continuing Education
Neoadjuvant and Adjuvant Treatment in Early Stage NSCLC: Options Are Expanding
FEATURING
Justin Gainor,
Jacob Sands
- 217 views
- September 5, 2023
- 2
Integrity CE
Targeted Treatment of Myelofibrosis: Novel Pathways & Mechanisms of Action for New & Emerging Agents
FEATURING
Ruben Mesa,
Aaron Gerds
- 147 views
- September 5, 2023
Integrity CE
New Frontiers in the Targeted Treatment of Myelofibrosis: Second-Generation JAK Inhibitors
FEATURING
Ruben Mesa,
Aaron Gerds
- 27 views
- September 5, 2023